Education Library

Mind & Consciousness · Article

Internet of Bodies

Implantable sensors, neural interfaces, continuous monitors — the infrastructure being built inside the human body, who controls the data, and what consent looks like.

Rev. Allie Johnson

Sanctified Healer · Monastic Medicine Practitioner

Tech Wearables & the Internet of Bodies

The World Economic Forum published a white paper in 2020 defining the "Internet of Bodies" — a framework for networked devices that attach to, enter, or integrate with the human body. It is not a conspiracy. It is a documented industrial roadmap. And it has a consumer on-ramp: the wellness market.

The same AI infrastructure that manages water treatment plants, IRS tax processing, and banking systems is being extended to the human body. The body becomes the final node in a network that already controls critical infrastructure. Understanding that arc — from wearable to networked — is the informed consent question of our time.

The Three Tiers of IoB

The IoB is not a single product or program. It is an architecture with three escalating layers — each building on the last, each normalizing the next.

Devices worn on the body that continuously collect biometric data and transmit wirelessly. Smartwatches (Apple Watch, Garmin), fitness trackers (Fitbit, Whoop), continuous glucose monitors (Dexcom, Libre), sleep rings (Oura), HRV monitors, at-home EKG devices (AliveCor/KardiaMobile), wireless blood pressure cuffs, ketone meters with app sync, and wellness-branded patches with app connectivity. All emit low-level radiofrequency radiation continuously and are worn in skin contact for extended periods.

Bioresonance scanning devices — AoScan, Zito Scan, and similar devices — also occupy this tier. They market themselves as diagnostic tools that read the body's electromagnetic frequencies. Regardless of whether their diagnostic claims are valid, these devices do collect body-proximate data and transmit it to cloud systems. They are IoB entry points wearing wellness branding.

This is the consumer entry point — normalized by the wellness market before anyone frames it as surveillance infrastructure.

Smart pills with sensors that transmit data after ingestion (FDA-approved since 2017 — Abilify MyCite was the first). Sub-dermal glucose monitors (Eversense, implanted in the upper arm). Microchip implants for payments and access control — already commercially available in Europe. RFID and NFC microchips implanted in the hand by employees at companies including a Wisconsin tech firm in 2017. Tier 1 builds the habit. Tier 2 moves the hardware inside.

Neural recording and stimulation implants. Neuralink received FDA approval for human trials in 2023 — first patient implanted January 2024. Synchron's Stentrode (implanted via blood vessel) is also in trials. DARPA has funded BCI research extensively through its N3 (Next-Generation Nonsurgical Neurotechnology) program. The progression from wellness wearable to neural interface is not a leap — it is a documented continuum. Each tier is the consumer market for the next.

Before Tier 1: Where the Technology Was First Tested

The first continuous body-worn electronic monitoring device was not a wellness product. It was an ankle bracelet — developed in the early 1980s by Judge Jack Love, who was inspired by a Spiderman comic, and first deployed on probationers in Albuquerque, New Mexico in 1983. The device used radio frequency signals to confirm location continuously and transmit that data to a monitoring center. It was worn by people who had no legal ability to refuse.

The Technology Was Field-Tested on People Who Could Not Say No

For two decades, continuous body-worn surveillance technology was normalized in the criminal justice system — on prisoners, parolees, and probationers. It was tested, refined, and proven at scale on a population that could not opt out. The architecture that emerged from that testing — body-worn sensor, continuous transmission, centralized monitoring — is the same architecture now built into the Oura ring, the Whoop strap, the Apple Watch, and the continuous glucose monitor. The hardware is smaller. The branding is wellness. The data pipeline is the same.

That lineage is not an analogy. It is a direct technological and institutional progression from coerced monitoring to consumerized monitoring. The key difference is that the consumer version requires your active purchase. Whether that constitutes genuine informed consent — given what is not disclosed about the data architecture — is the question this page was written to help you answer for yourself.

The Network Standard Behind the Devices

The infrastructure behind IoB devices is not improvised. It has a formal technical standard: IEEE 802.15.6-2012 — the Wireless Body Area Network (WBAN) specification. Adopted in 2012, this standard defines the communication protocol for devices that operate on or around the human body: frequency bands, power levels, topology, and data formats. The network architecture for the connected human body was standardized over a decade ago. The consumer products are the deployment layer.

IEEE Std 802.15.6-2012. "IEEE Standard for Local and Metropolitan Area Networks — Part 15.6: Wireless Body Area Networks." IEEE, February 2012. — defines WBAN operating bands including 2.4 GHz ISM band, Medical Implant Communications Service (MICS) 402–405 MHz, and ultrawideband.

What the Engineering Literature Documents

A 2023 peer-reviewed review in the Alexandria Engineering Journal (Nunna, Kuchhal, Varshney — Creative Commons license) maps the current state of wearables and implantables operating in the MICS band. The FCC allocated the Medical Body Area Network (MBAN) spectrum in 2012. Congressional hearings in 2014 addressed the policy and infrastructure implications of that allocation. This buildout required — and received — coordinated participation from electrical engineers, biomedical engineers, nanotechnologists, computer scientists, and information technology architects, coordinated at the federal level through the National Nanotechnology Initiative (nano.gov) across 20+ agencies including DARPA, NIH, NSF, and the FDA.

MICS Band — Inside the Body, Wireless, FCC-Regulated

The 402–405 MHz band is reserved by the FCC for devices that operate from within the human body. Pacemakers, neurostimulators, cochlear implants, ingestible biosensors, and implantable glucose monitors communicate in this range — wirelessly, through skin and tissue, to external receivers. The 2023 Nunna et al. review documents the current device landscape, antenna miniaturization, and the materials science enabling implant-scale wireless communication. This is not an emerging concept. It is a federally coordinated active buildout with its own spectrum allocation, its own engineering standard, and its own 20-year federal funding history.

Graphene, Metamaterials, and the Materials Science Layer

Implantable biosensors small enough to operate in the MICS band require materials that are biocompatible, electrically conductive, and immune-tolerated in tissue. Graphene — a single-atom-thick carbon lattice — is the primary candidate in the peer-reviewed engineering literature because it meets all three criteria. Metamaterials (engineered composites with electromagnetic properties not occurring in nature) are used in implant-scale antenna design. The National Nanotechnology Initiative has coordinated federal funding for exactly this materials layer for over two decades through nano.gov.

Networked Biosensors and MAC ID Architecture

Every networked device requires a unique hardware identifier to communicate with receivers and cloud systems. Implantable biosensors carry MAC addresses (Media Access Control IDs) that function exactly as a computer's network identifier does. Living cell-based biosensors — which use human or mammalian cells as the biological sensing element — are an active engineering research area. A networked sensor made from human cells, implanted in a human body, carrying a unique device ID, and transmitting to cloud infrastructure simultaneously raises questions of engineering, biology, identity, and data sovereignty that no consumer disclosure currently addresses.

Lipid Nanoparticles as a Delivery Mechanism

The lipid nanoparticle (LNP) is a nanoscale fat bubble that carries a payload through biological membranes into cells. It entered widespread public awareness through mRNA vaccine formulations. In the nanotechnology literature — including NNI published roadmaps — LNPs and similar lipid-based carriers are explored as delivery vehicles for nanoscale biosensors, therapeutic agents, and implantable payloads that need to reach specific tissue targets without surgery. The delivery technology and the sensor technology are being developed in parallel, by overlapping research communities, under coordinated federal funding. The phrase "loaded the nanoparticles" appears in the engineering literature as a straightforward technical description of payload preparation — not metaphor.

The Documented Roadmap: WEF 2020

World Economic Forum — "Shaping the Future of the Internet of Bodies" (2020)

In September 2020, the World Economic Forum published a white paper co-authored with the RAND Corporation laying out the IoB framework. Key passages:

  • "The IoB ecosystem consists of a vast array of devices connected to the human body and each other via the internet."
  • The paper explicitly categorizes devices by tier: body-external, body-internal, body-embedded.
  • It acknowledges that "the IoB raises numerous legal and ethical issues related to privacy, security, and bodily integrity."
  • It recommends regulatory frameworks not to stop IoB deployment but to "govern" it — the presumption is deployment.
  • No equivalent public consent framework for the individuals whose bodies are being networked is proposed.

Internet of Behaviors: When the Data Changes Your Access

The IoB does not only collect data. It uses that data to modify behavior — and in some implementations, to revoke access. Gartner, the technology research firm, introduced the "Internet of Behaviors" (IoB) concept in its 2021 Strategic Technology Trends report. It described systems that use behavioral data collected from connected devices to influence what people do — and in some cases, to control what they can access.

Gartner 2021 — Key Findings

  • By the end of 2023, Gartner projected that more than 40% of the global population would have behavioral data captured by IoB technology.
  • "Organizations will use the IoB to capture, analyze, and respond to human behavior to achieve desired outcomes."
  • Examples include: insurance companies monitoring driving behavior via connected car data; employers tracking employee mood and engagement via wearables; retail environments measuring customer attention and emotional response.
  • Access revocation mid-session: Gartner described systems capable of adjusting access, pricing, or services in real time based on behavioral flags — including health status indicators from wearables.

European Data Protection Supervisor (EDPS) Assessment

The EDPS TechDispatch #2/2021 assessed IoB and Internet of Behaviors technology. It concluded that behavioral data collected from connected devices "enables identification, profiling, and potentially manipulation of individuals on a vast scale." It noted that GDPR protections apply to EU residents, but that equivalent protections do not exist in most jurisdictions — and that consumer wellness devices fall outside healthcare data frameworks entirely.

The Data Problem

Biometric data has properties that make it categorically different from other personal data:

It Cannot Be Changed

A compromised password can be reset. A compromised email address can be changed. Your heart rate variability signature, your gait pattern, your glucose response curve, your retinal pattern, your iris, your face — these cannot be changed. Once biometric data has been collected and associated with your identity, the compromise is permanent.

It Reveals What You Haven't Disclosed

HRV data reveals stress levels, illness onset, alcohol and drug use, menstrual cycle phase, pregnancy, and mental health states. Glucose data reveals diet, metabolic health, insulin resistance, and alcohol use. Sleep data reveals work schedules, relationship patterns, and behavioral rhythms. None of this requires active disclosure — it is inferred from the continuous data stream.

It Is Retroactively Interpretable

Data collected today can be analyzed with tools that don't yet exist. A biometric dataset from 2024 will be more interpretable in 2034 than it is now. Consent given in 2024 does not account for what that data will reveal — or be used for — in a decade.

It Cannot Be Anonymized

Research consistently shows that biometric datasets labeled "anonymous" or "de-identified" can be re-identified with high accuracy when combined with other available data. Location data, purchasing data, social media activity, and biometric streams together create a unique fingerprint. "De-identified" is a legal designation, not a technical guarantee.

Questions Worth Asking

This is educational information, not clinical advice. The questions below are ones informed people ask before connecting their bodies to networked systems.

About any wearable or monitoring device

  • Does this device transmit continuously, or only when synced manually?
  • Who receives the data, and does the privacy policy disclose sharing with "partners," insurers, or research entities?
  • Is this device connected to an employer wellness program? If so, what is the data pathway to the employer?
  • What are the state laws regarding smart meter opt-out in my area?
  • What is the EMF emission profile of this device when worn during sleep?

About ingestibles and implantables

  • Sub-dermal CGMs (Eversense) and smart pills (Abilify MyCite) represent a different category of data access than surface wearables — the device is inside the body, transmitting continuously, with no mechanism to turn it off between replacements. What are the data rights?
  • RFID/NFC microchip implants create a permanent hardware interface that can be read remotely. What access does the issuing company retain?

About neural interfaces and BCI devices

  • What are the data rights for neural recordings? Who owns the data — the patient, the hospital, or the device company?
  • What happens to the neural data if the company is acquired or goes bankrupt?
  • What is the wireless security posture of a brain-connected transmitting device?
  • For therapeutic BCIs (epilepsy, Parkinson's, spinal cord injury): these questions apply equally — the therapeutic framing does not change the data architecture.

The informed consent that should exist — and doesn't

You can't consent to what you've never been told. The wellness device on your wrist, the smart meter on your wall, the remote monitoring device your doctor ordered — none of these came with an informed consent process that disclosed who has your data, for how long, and for what purposes. That disclosure gap is not an oversight. It is a design feature.

Ready to go deeper?

Fellowship opens the door to personal ministry support from Rev. Allie — applied to your specific path.

Enter into Fellowship